- 8.28.2025
- News
- Press Releases
Beyond the One Dose Wonder: Why Psychedelic Clinical Trial Protocols Must Evolve Beyond Academic Norms
When most people hear about psychedelic clinical trials, they envision a single, transformative session, maybe two, resulting in rapid, life-changing outcomes. But the reality is more complex.
Hope Has Data: The Science Behind Psychedelic Healing for Veterans
This blog explores the growing body of evidence supporting psychedelic-assisted therapy as a powerful, trauma-informed treatment option for veterans with PTSD and TBI. Highlighting data, personal stories, and VETS’ commitment to research and access, it underscores how science and compassion are transforming the future of healing.
- 8.19.2025
- News
Netflix Picks Up Documentary ‘In Waves and War’; Releasing in November 2025
In Waves and War – Premiering on Netflix in November 2025, this documentary follows Navy SEAL veteran Marcus Capone and his wife Amber as they navigate the challenges of PTSD and TBI after service. Their journey with psychedelic-assisted therapy leads to the founding of Veterans Exploring Treatment Solutions (VETS), an organization dedicated to helping other veterans access innovative care and confronting the veteran suicide epidemic.
- 8.19.2025
- News
SXSW Is Taking Votes On Dozens Of Marijuana And Psychedelics Panel Proposals For 2026 Festival
South by Southwest (SXSW) is inviting public input on dozens of proposed panel sessions for its 2026 festival, spanning topics in both marijuana and psychedelics. Among the highlights are sessions that explore cannabis justice, the mainstreaming of hemp and THC products in retail, the creative potential of psychedelic experiences, and transformative care with emerging therapies like ibogaine. Panel topics also spotlight the Texas Ibogaine Initiative’s impact on treating PTSD, TBI, and opioid use disorders among veterans, alongside discussions on psychedelic healing for first responders, brain injury recovery, and even neuroscience in outer space
Stepping Into Service: A Note from Our New Director of Research
John Clifton, M.D., the new Director of Research at VETS, brings a decade of experience in psychedelic healing and a vision for advancing safe, trauma-informed, and evidence-based therapies for veterans. In this welcome message, he shares his reflections on the state of the field, the urgent need for research and policy reform, and his commitment to empowering community-driven learning.
- 8.1.2025
- News
Combat Cocktail: How America Overmedicates Veterans
A new Wall Street Journal report reveals the VA is prescribing risky drug combinations to hundreds of thousands of veterans with PTSD—despite known risks and internal warnings. The article underscores the urgent need for safer, more effective treatments like those VETS supports through research, advocacy, and access to psychedelic-assisted therapies.
- 8.1.2025
- Blog
Freedom to Heal: What It Means And Why We’re Fighting For It
At VETS, we believe that healing is a right, not a privilege. That’s what we mean by Freedom to Heal. It’s not just a phrase. It’s a promise. And it’s the driving force behind everything we do.
- 7.25.2025
- News
Ibogaine: The Fight of a Lifetime
“Ibogaine: The Fight of a Lifetime” is a Fox Nation news segment highlighting the experiences of Special Operations veterans pursuing psychedelic-assisted therapy to address traumatic brain injury and PTSD.
- 7.23.2025
- News
Advocates want NC legislature to consider rules around psychedelics for PTSD treatment
Advocates in North Carolina are urging lawmakers to support Senate Bill 568, which would create a task force to explore safe, regulated access to psychedelic-assisted therapy for PTSD—especially for veterans. While not legalizing psychedelics, the bill aims to prepare the state for future FDA approval through infrastructure planning and veteran-focused care.
- 7.16.2025
- News
RFK Jr. and other Trump officials embrace psychedelics after FDA setback
RFK Jr. and former Trump officials are backing psychedelic therapies like MDMA and ibogaine, pushing for FDA approval amid growing bipartisan interest. The article highlights veteran voices, including VETS' Marcus Capone, advocating for access despite safety concerns.